Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations

Prajjval Pratap Singh, Rakesh Tamang, Manoj Shukla, Abhishek Pathak and Serosurveillance consortium Banaras Hindu University, Varanasi, India (full author list at the last page)

Correspondence to: gyaneshwer.chaubey@bhu.ac.in

Keywords: Antibody, Coronavirus, India, Seroprevalence, Herd immunity

Abstract

Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depressions. Europe and America were the hardest hit continents. India has also lost several lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than many of the developed nations. Several factors have been proposed including the genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission among states. We also found out that the cases reported by the Government were several fold lower than the real infection. This discrepancy is majorly driven by a higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, it is less likely to have a second wave in India.

Introduction

The whole world has been fighting the COVID-19 epidemic for over a year. During this time, the number of people who died due to infection of this virus in the globe has also crossed a mark of 2 millions (Dong et al., 2020). Before the roll-out of vaccination recently, it was highly challenging for a nation to stop the spread of this virus. Several of the standard precautionary measures e.g. strict lockdown, use of mask, frequent hand hygiene, social distancing, contact tracing and quarantine have been applied widely (Jung et al., 2020; Rodriguez-Palacios et al., 2020). Even after this, no country is yet in such a condition that it can declare itself completely free from it. Initially, herd immunity was also considered and discussed widely (Randolph and Barreiro, 2020; Slot et al., 2020).

Herd immunity against the SARS-CoV-2 is one of the highly debated topic (Anderson and May, 1985; Bock et al., 2020; Frederiksen et al., 2020; Jung et al., 2020; Kwok et al., 2020; Neagu, 2020). During the pandemic when approximately 70% of the population infect and develop antibodies against the pathogen, it facilitates the herd immunity. This barrier of immunity blocks the virus and adds passive immunity to non-infected people. However, due to the high fatality rate of SARS-CoV-2 infection, nearly all of the countries did not adopt this strategy. For example, United Kingdom (UK) and Sweden have opted where UK abandoning it at the initial stage (Hunter, 2020; Sibony, 2020), whereas Sweden was heavily criticised with largest number of cases and fatalities in Scandinavia (Habib, 2020; Orlowski and Goldsmith, 2020). Thus, the plan of obtaining a rapid herd immunity was indeed an autophagy (Chaubey, 2020).

The model of herd immunity is very similar to the positive selection (or selective sweep), a term often used in the genomic studies (Sabeti et al., 2002; Voight et al., 2006). Similarly, we can also relate hard sweep and soft sweep terminology (Pritchard et al., 2010), for a soft and hard herd immunity. With the exclusion of hard herd immunity, the alternate option was to obtain the soft herd immunity with strict use of defensive procedures. Protective measures like strict lockdown, use of masks, frequent hand hygiene and social distancing have significantly reduced the effective infections and overburden to the emergency services (Aleta et al., 2020; West et al., 2020). Also with the efficacious contact tracing and quarantine, one may achieve soft herd immunity with period of time (Aleta et al., 2020).

From the first case in India on 30^{th} Jan 2020, now the total cases have been surpassed to >10 million with >0.15 million fatalities (Coronavirus in India: Latest Map and Case Count). Although still the new number of cases are between 10-15,000 per day, India has followed a perfect bell-shaped curve with a well-defined peak in September 2020. Several studies have pinpointed that the real number of infected people in a population are several fold higher than the reported cases (Aspelund et al., 2020; Böhning et al., 2020; Ivorra et al., 2020; Mukhopadhyay and Chakraborty, 2020; Pedersen and Meneghini, 2020; Shaman, 2020). In addition with that, a large number of asymptomatic people add another layer of complexity to it which have been seen in case of India (Chaubey, 2020). Most of the studies relied upon the mathematical modelling which may not show the real picture of COVID-19 in India ((Arti and Bhatnagar, 2020; Chatterjee et al., 2020a, 2020b; Mukhopadhyay and Chakraborty, 2020; Tiwari, 2020). The random antibody testing in a population is one of the procedures to obtain the realtime picture of the developed immunity. Thus, to understand the COVID-19 dynamics in India, we have performed the real-time antibody testing on urban populations from fourteen districts of India. The aim was to estimate the level of immunity against COVID-19 among urban street vendors.

Materials and Methods

Since most of the COVID-19 cases in India were concentrated on urban areas, we have selected urban populations in our survey. During the month of September-December 2020, we randomly surveyed healthy working individuals who have neither been diagnosed with COVID-19, nor had been sick with any associated symptom in the recent past. Moreover, we excluded those individuals in our survey whose family members have been ever diagnosed with the COVID-19 in the past. Our focus was to screen people from urban vendor group who are relatively more exposed in the society e.g. roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw drivers, milkman, hawkers etc. With these stringent criteria, we screened unrelated people who have not lived together.

We have used CoviscreenTM kit, kindly provided by Biosense Technologies, India to screen the individuals for the presence of antibodies. This kit detects the total antibody (IgM+IgA+IgG) present in the blood. We followed the manufacturers protocol for the detection. A sample test for positive and negative samples have been shown in

Supplementary Figure 1. Complete details about this kit can be obtained from the supplier http://www.tulipgroup.com/Covid19/Covid19.html.

The frequency of Antibody positive individuals were calculated in each of the districts surveyed (Table 1). The districtwise geographical frequency map was generated by https://www.datawrapper.de/. Frequency bar plot of each district was drawn with 95%CI (Figure 1). District-wise population census data was extracted from the 2011 census of India (Census of India Website 2: Office of the Registrar General & Census Commissioner, India). Numbers of reported cases in each district were recorded from the Covid India tracker (Coronavirus in India: Latest Map and Case Count). This study has been approved by the Institutional Ethical Committee of Banaras Hindu University, Varanasi, India.

Results and Discussion

In our survey, geographically we have covered districts from Western, Northern, Eastern, Central and Southern regions of India. Two districts were covered from Western part (Gujarat), seven districts were surveyed in Northern part (Uttar Pradesh), three districts from Central part (Madhya Pradesh and Chhattisgarh), whereas single district each of Eastern (West Bengal) and Southern (Karnataka) regions were surveyed (Table 1). Our seroprevalence survey in fourteen districts of six states have shown high level of variability among the regions (Supplementary Fig. 2). The minimum antibody positive people were observed in Raipur district of Chhattisgarh state, whereas maximum antibody positive individuals were found in Ghazipur district of Uttar Pradesh state (Figure 1 and Table 1). The mean seroprevalence among studied districts was 0.306 (95%CI 0.287-0.325). The high prevalence of antibodies in many of the districts suggests that the soft herd immunity in India is underway. The frequency of antibody positive people is sporadic, however regions like Eastern Uttar Pradesh showed largely a uniform seroprevalence (Fig. 1 and Supplementary Fig. 2). The mean value in this region was found to be 0.41 (95% CI 0.38-0.44). Major districts of this region like Varanasi, Jaunpur and Ghazipur all had a frequency of >0.40 seroprevalence. The variation among districts suggests that the level of virus spread among districts of India is asymmetrical.

Notably, all the participants in this study were found to be asymptomatic, they did not know that they ever had COVID-19. This suggests that a large proportion of Indian population is asymptomatic against SARS-CoV-2 infection. Indeed, there might be several known and unknown rationales behind that, however the prevalence of rs2285666 associated haplotype (Srivastava et al., 2020) and 35 years or younger age of \sim 65% of Indian populations, are two highly likely explanations.

In order to understand the magnitude of unreported cases, we have compared the frequency of government reported cases with the frequency of antibody positive cases. All of the districts showed higher seroprevalence than reported cases (Table 1). The mean value of studied districts was 17 times (95% CI 13-22) higher than the government reported cases. Similar with the frequency dissimilarities, in statewise comparison, we observed substantial differences e.g. 40 times in Gujarat, 21 times in Uttar Pradesh, 23 times in Madhya Pradesh, 0.2 times in Chhattisgarh, 9 times in West Bengal and 5 times in Karnataka. Interestingly, we found out that cases reported by the Government were highly correlated with the urban census (two tailed p<0.0001), whereas we did not find any significant correlation between antibody positive frequency with urban census or government reported cases.

As our result suggests that the number of real infections in India is several fold higher than the Government reported cases, we may reconsider the case fatality ratio. The present case fatality ratio of India (1.44) is significantly lower (two tailed p value <0.0001) than global average (2.15). Considering our result which shows a far greater number of real infected people, the actual case fatality ratio of India is at least 17 times lower (Table 1).

Our observation at the fourteen districts of India indicates sporadic high level of immunity among people who are highly contagious as well as exposed. Since our focus was on the people who are more prone to receive as well as spread infection. Our result advocates that a strong level of immunity wall has been already in effect. Keeping in mind such a scenario it is likely that most of the hotspots are saturated with the immune people. This is why the number of daily infections are decreasing and the chance of a second wave is highly unlikely.

In summary, for the first time we have used a novel approach to estimate the developed immunity against SARS-CoV-2 among the exposed population of fourteen districts. These results strongly indicate that the soft herd immunity is already in force in most of the Indian territory. We observed that on an average every third street vendor in majority of the studied districts is immune against SARS-CoV-2. The number of asymptomatic cases in India is much higher than expected. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of districts, it is unlikely to have a second wave in India.

Acknowledgements

We are grateful to the Biosense Technologies, India for their kind help in this project. We did not receive any specific funding for this project.

Data Availability Statement

All datasets generated for this study are included in the article/Supplementary Material.

Competing interests: The authors declare no competing interests.

Conflict of Interest

Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

- Aleta, A., Martin-Corral, D., y Piontti, A. P., Ajelli, M., Litvinova, M., Chinazzi, M., et al. (2020). Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. *Nat. Hum. Behav.* 4, 964–971.
- Anderson, R. M., and May, R. M. (1985). Vaccination and herd immunity to infectious diseases. *Nature* 318, 323–329.
- Arti, M. K., and Bhatnagar, K. (2020). Modeling and predictions for COVID 19 spread in India. *No April*.
- Aspelund, K. M., Droste, M. C., Stock, J. H., and Walker, C. D. (2020). Identification and estimation of undetected COVID-19 cases using testing data from Iceland.

 National Bureau of Economic Research.
- Bock, W., Adamik, B., Bawiec, M., Bezborodov, V., Bodych, M., Burgard, J. P., et al. (2020). Mitigation and herd immunity strategy for COVID-19 is likely to fail. *medRxiv*.
- Böhning, D., Rocchetti, I., Maruotti, A., and Holling, H. (2020). Estimating the undetected infections in the Covid-19 outbreak by harnessing capture–recapture methods. *Int. J. Infect. Dis.* 97, 197–201.
- Census of India Website 2: Office of the Registrar General & Census Commissioner, India Available at: https://censusindia.gov.in/2011-common/censusdata2011.html [Accessed January 5, 2021].
- Chatterjee, K., Chatterjee, K., Kumar, A., and Shankar, S. (2020a). Healthcare impact of COVID-19 epidemic in India: A stochastic mathematical model. *Med. J. Armed Forces India* 76, 147–155.
- Chatterjee, S., Sarkar, A., Chatterjee, S., Karmakar, M., and Paul, R. (2020b). Studying the progress of COVID-19 outbreak in India using SIRD model. *Indian J. Phys.*, 1–17.
- Chaubey, G. (2020). Coronavirus (SARS-CoV-2) and Mortality Rate in India: The Winning Edge. *Front. Public Health* 8, 397. doi:10.3389/fpubh.2020.00397.
- Coronavirus in India: Latest Map and Case Count Available at: https://www.covid19india.org [Accessed May 13, 2020].
- Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.*
- Frederiksen, L. S. F., Zhang, Y., Foged, C., and Thakur, A. (2020). The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. *Front. Immunol.* 11.
- Habib, H. (2020). Has Sweden's controversial covid-19 strategy been successful? *bmj* 369.

- Hunter, D. J. (2020). Covid-19 and the stiff upper lip—The pandemic response in the United Kingdom. *N. Engl. J. Med.* 382, e31.
- Ivorra, B., Ferrández, M. R., Vela-Pérez, M., and Ramos, A. M. (2020). Mathematical modeling of the spread of the coronavirus disease 2019 (COVID-19) taking into account the undetected infections. The case of China. *Commun. Nonlinear Sci. Numer. Simul.* 88, 105303.
- Jung, F., Krieger, V., Hufert, F. T., and Küpper, J.-H. (2020). Herd immunity or suppression strategy to combat COVID-19. *Clin. Hemorheol. Microcirc.*, 1–5.
- Kwok, K. O., Lai, F., Wei, W. I., Wong, S. Y. S., and Tang, J. W. (2020). Herd immunity-estimating the level required to halt the COVID-19 epidemics in affected countries. *J. Infect.* 80, e32–e33.
- Mukhopadhyay, S., and Chakraborty, D. (2020). Estimation of undetected COVID-19 infections in India. *medRxiv*.
- Neagu, M. (2020). The bumpy road to achieve herd immunity in COVID-19. *J. Immunoassay Immunochem.*, 1–18.
- Orlowski, E. J., and Goldsmith, D. J. (2020). Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight. *J. R. Soc. Med.* 113, 292–298.
- Pedersen, M. G., and Meneghini, M. (2020). Quantifying undetected COVID-19 cases and effects of containment measures in Italy. *Res. Prepr. Online 21 March 2020 DOI* 10.
- Pritchard, J. K., Pickrell, J. K., and Coop, G. (2010). The Genetics of Human Adaptation: Hard Sweeps, Soft Sweeps, and Polygenic Adaptation. *Curr Biol* 20, R208–R215. doi:10.1016/j.cub.2009.11.055.
- Randolph, H. E., and Barreiro, L. B. (2020). Herd immunity: understanding COVID-19. *Immunity* 52, 737–741.
- Rodriguez-Palacios, A., Cominelli, F., Basson, A., Pizarro, T., and Ilic, S. (2020). Textile Masks and Surface Covers-A'Universal Droplet Reduction Model'Against Respiratory Pandemics. *medRxiv*.
- Sabeti, P. C., Reich, D. E., Higgins, J. M., Levine, H. Z., Richter, D. J., Schaffner, S. F., et al. (2002). Detecting recent positive selection in the human genome from haplotype structure. *Nature* 419, 832–7.
- Shaman, J. (2020). An estimation of undetected COVID cases in France. Nature Publishing Group.
- Sibony, A.-L. (2020). The UK COVID-19 Response: A Behavioural Irony? *Eur. J. Risk Regul.*, 1–11.

- Slot, E., Hogema, B. M., Reusken, C. B., Reimerink, J. H., Molier, M., Karregat, J. H., et al. (2020). Herd immunity is not a realistic exit strategy during a COVID-19 outbreak.
- Srivastava, A., Pandey, R. K., Singh, P. P., Kumar, P., Rasalkar, A. A., Tamang, R., et al. (2020). Most frequent South Asian haplotypes of ACE2 share identity by descent with East Eurasian populations. *PLOS ONE* 15, e0238255. doi:10.1371/journal.pone.0238255.
- Tiwari, A. (2020). Modelling and analysis of COVID-19 epidemic in India. *J. Saf. Sci. Resil.* 1, 135–140.
- Voight, B. F., Kudaravalli, S., Wen, X., and Pritchard, J. K. (2006). A map of recent positive selection in the human genome. *PLoS Biol* 4. doi:10.1371/journal.pbio.0040072.
- West, R., Michie, S., Rubin, G. J., and Amlôt, R. (2020). Applying principles of behaviour change to reduce SARS-CoV-2 transmission. *Nat. Hum. Behav.* 4, 451–459.

Figure Legend:

Figure 1. The bar plot showing seroprevalence frequency (CI95%) among studied districts. The districts are also grouped in to states.

Supplementary Figure 1. The detection of antibodies by the CoviscreenTM kit. The kit produce one and two bands in case of Antibody negative and positive persons respectively.

Supplementary Figure 2. The geospatial frequency of antibodies with our sampling locations.

Table 1. The detailed districtwise data of seroprevalence. Frequency of Government cases has been calculated by number of reported cases/urban census. Number of times were calculated by dividing seroprevalence with frequency of Government reported cases.

State	District	Months	N	Antibody+	Freq.(Ab+)	Freq.(Govt.)	Cases (Govt.)	Urban Census	Times
Gujarat	Ahmedabad	Dec-20	50	23	0.46 (0.329-0.597)	0.011	60848	5600000	42.3
Gujarat	Baroda	Dec-20	50	14	0.28 (0.175-0.417)	0.017	27755	1671000	16.9
Uttar Pradesh	Varanasi	Sept 2020-Dec 2020	406	166	0.409 (0.362-0.457)	0.012	23360	2000000	35.0
Uttar Pradesh	Jaunpur	Sept 2020-Dec 2020	263	116	0.441 (0.382-0.502)	0.019	6697	347000	22.9
Uttar Pradesh	Ghazipur	Sept 2020-Dec 2020	128	61	0.477 (0.392-0.563)	0.043	5236	121000	11.0
Uttar Pradesh	Mirzapur	Oct-20	100	30	0.30 (0.219-0.396)	0.014	3441	246000	21.4
Uttar Pradesh	Gorakhpur	Oct-20	98	38	0.388 (0.297-0.487)	0.031	21364	695000	12.6
Uttar Pradesh	Lucknow	Oct-20	72	27	0.375 (0.272-0.491)	0.029	81276	2817000	13.0
Uttar Pradesh	Jhansi	Nov-20	100	7	0.07 (0.035-0.138)	0.019	10399	548000	3.7
Madhya Pradesh	Sagar	Sept 2020-Dec 2020	250	98	0.392 (0.334-0.454)	0.015	5367	370000	27.0
Madhya Pradesh	Singrauli	Sept 2020-Oct 2020	384	59	0.154 (0.121-0.193)	0.008	1907	227000	18.3
Chhattishgarh	Raipur	Sep-20	100	1	0.01 (0.002-0.054)	0.047	53106	1124000	0.2
West Bengal	Kolkata	Dec-20	100	8	0.08 (0.042-0.15)	0.009	127656	14036000	8.8
Karnataka	Mangalore	Dec-20	200	55	0.275 (0.218-0.341)	0.054	33701	624000	5.1

Full author list-

Prajival Pratap Singh¹, Rakesh Tamang², Manoj Shukla³, Abhishek Pathak⁴, Anshika Srivastava¹, Pranav Gupta⁵, Alay Bhatt⁶, Abhishek K. Shrivastava⁷, Sudhir K. Upadhyay⁸, Ashish Singh⁹, Sanjeev Maurya⁹, Purnendu Saxena¹⁰, Vanya Singh¹, Akhilesh Kumar Chaubey¹¹, Dinesh Kumar Mishra¹², Yashvant Patel¹, Rudra Kumar Pandey¹, Ankit Srivastava¹³, Nargis Khanam¹, Debashruti Das¹, Audditiya Bandopadhyay¹, Urgyan Chorol¹, Nagarjuna Pasupuleti^{14,15}, Sachin Kumar Shrivastav¹⁴, Satya Prakash¹⁴, Astha Mishra^{14,16}, Pavan Kumar Dubey¹⁷, Ajit Parihar¹⁸, Priyoneel Basu¹⁹, Jaison J Sequeira¹⁵, Lavanya KC¹⁵, Vijayalaxmi¹⁵, Vishnu Shreekara Bhat. K. ¹⁵, Thadiyan Parambil Ijinu²⁰, Dau Dayal Aggarwal²¹, Anand Prakash²², Kiran Yadav²³, Anupam Yadav²³, Vandana Upadhyay²⁴, Gunjan Mukim², Ankan Bhandari², Ankita Ghosh², Akash Kumar¹³, Vijay Kumar Yadav¹³, Kriti Nigam¹³, Abhimanyu Harshey¹³, Tanurup Das¹³, Deepa Devadas²⁵, Surendra Pratap Mishra²⁶, Ashish²⁵, Abhay Kumar Yadav²⁵, Nitish Kumar Singh²⁵, Manpreet Kaur²⁵, Sanjay Kumar¹⁹, Nikhil Srivastava¹, Charu Sharma¹, Ritabrata Chowdhury¹, Dharmendra Jain²⁷, Abhai Kumar⁴, Ritesh Shukla⁵, Raghav Kumar Mishra²³, Royana Singh^{19,25}, Yamini B Tripathi³, Vijay Nath Mishra⁴, Mohammed S. Mustak¹⁵, Niraj Rai¹⁴, Sumit Kumar Rawat²⁸, Prashanth Survajhala²⁹, Keshav K Singh³⁰, Chandana Basu Mallick³¹, Pankaj Shrivastava³² and Gyaneshwer Chaubey¹

Prajjval Pratap Singh, Rakesh Tamang, Manoj Shukla and Abhishek Pathak - equal first author contribution

- ¹Cytogenetics Laboratory Department of Zoology, Banaras Hindu University, India
- ²Department of Zoology, University of Calcutta, India
- ³Department of Medicinal Chemistry, Institute of Medical Science, Banaras Hindu University, India
- ⁴Department of Neurology, Institute of Medical Science, Banaras Hindu University, India ⁵Independent Researcher, Varanasi, India
- ⁶Biological and Life Sciences, School of Arts and Sciences, Ahmedabad University, India
- ⁷Department of Biotechnology, Mohd. Hasan P. G. College, Jaunpur, India
- ⁸Department of Environmental Science, Veer Bahadur Singh Purvanchal University, Jaunpur, India
- ⁹Genome Foundation Rural Centre Kalavari, Jaunpur, India, 222131
- ¹⁰VY Hospital, Raipur, Chhattisgarh, India
- $^{11}{\rm Krishi}$ Vigyan Kendra, Singrauli, Jawaharlal Nehru Krishi Vishwavidyalay, Jabalpur, Madhya Pradesh, India
- ¹²Mishra Polyclinic, Waidhan, Madhya Pradesh, India, 486886
- ¹³Dr. A.P.J. Abdul Kalam Institute of Forensic Science & Criminology, Bundelkhand University, Jhansi, India
- ¹⁴Birbal Sahni Institute of Palaeosciences, Lucknow, India
- ¹⁵Department of Applied Zoology, Mangalore University, Mangalagangothri-574199, Mangalore, Karnataka, India
- ¹⁶Amity University, Noida, Uttar Pradesh, India
- ¹⁷Prosthodontics Unit, Faculty of Dental Sciences, Institute of Medical Sciences, Varanasi, India
- ¹⁸Orthodontics Unit, Faculty of Dental Sciences, Institute of Medical Sciences, Varanasi, India

- ¹⁹Multidisciplinary Research Unit, Institute of Medical Science, Banaras Hindu University, India
- ²⁰Amity Institute for Herbal and Biotech Products Development, 3-Ravi Nagar, Peroorkada, Thiruvananthapuram 695005, Kerala, India
- ²¹Department of Biochemistry, University of Delhi, South Campus, New Delhi, India
- ²²Sardar Ballabhbhai Patel College, Bhabua Kaimur, Bihar, India
- ²³Male Reproductive Physiology Laboratory, Department of Zoology, Banaras Hindu University, India
- ²⁴Abhay Degree College, Varanasi, India
- ²⁵Department of Anatomy, Institute of Medical Science, Banaras Hindu University, India
- ²⁶Department of Biochemistry, Institute of Medical Science, Banaras Hindu University, India
- ²⁷Department of Cardiology, Institute of Medical Science, Banaras Hindu University, India
- ²⁸Department of Microbiology, Bundelkhand Medical College, Sagar, India
- ²⁹Department of Biotechnology and Bioinformatics, Birla Institute of Scientific Research Statue Circle, Jaipur, Rajasthan, India
- ³⁰Department of Genetics, School of Medicine, University of Alabama at Birmingham, Kaul Genetics Building, Birmingham, Alabama
- ³¹Centre for Genetic Disorders, Banaras Hindu University, India
- ³²DNA Fingerprinting Unit, State Forensic Science Laboratory, Department of Home (Police), Government of MP, Sagar, India

